Working... Menu
Trial record 1 of 1 for:    "Hereditary Transthyretin Amyloidosis" | "Diflunisal"
Previous Study | Return to List | Next Study

Monitoring of Early Disease Progression in Hereditary Transthyretin Amyloidosis (MED-hATTR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03431896
Recruitment Status : Recruiting
First Posted : February 13, 2018
Last Update Posted : March 1, 2019
Information provided by (Responsible Party):
Mazen Hanna MD, The Cleveland Clinic

No Study Results Posted on for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : February 15, 2024
  Estimated Study Completion Date : February 15, 2024